Fig. 1From: The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ ageROC curve analysis of the association between TMB and DCB in young and elderly patients in NSCLC. ROC curves of (a) Rizvi cohort, (b) Hellmann cohort. ROC: receiver operator characteristic; TMB: tumor mutation burden; DCB: durable clinical benefit; NSCLC: non-small cell lung cancer; AUC: area under curve; CI: confidence intervalBack to article page